<![CDATA[Nogapendekin Alfa Combo Earns UAE Marketing Authorization in NMIBC, NSCLC]]>

Regulatoryapprovednogapendekin alfaPositive

AI Analysis

Summary

The UAE granted marketing authorization for nogapendekin alfa in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer and with checkpoint inhibitors for metastatic non-small cell lung cancer.

Outcome Details

UAE marketing authorization granted for nogapendekin alfa plus BCG in BCG-unresponsive NMIBC and with checkpoint inhibitors in metastatic NSCLC

Importance:5/10

Sentiment:

0.70

regulatory approvalUAENMIBCNSCLCimmunotherapy

Related Companies

$CKPT

Read the original article

Published by Cancer Network on July 30, 2026 5:00 PM

Read Original